Document Detail

Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's Disease.
MedLine Citation:
PMID:  23288978     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVE: To study whether sleep and circadian rhythm disturbances in patients with Huntington's disease (HD) arise from dysfunction of the body's master clock, the hypothalamic suprachiasmatic nucleus.
DESIGN: Postmortem cohort study.
PATIENTS: Eight patients with HD and eight control subjects matched for sex, age, clock time and month of death, postmortem delay, and fixation time of paraffin-embedded hypothalamic tissue.
MEASUREMENTS AND RESULTS: Using postmortem paraffin-embedded tissue, we assessed the functional integrity of the suprachiasmatic nucleus in patients with HD and control subjects by determining the expression of two major regulatory neuropeptides, vasoactive intestinal polypeptide and arginine vasopressin. Additionally, we studied melatonin 1 and 2 receptor expression. Compared with control subjects, the suprachiasmatic nucleus contained 85% fewer neurons immunoreactive for vasoactive intestinal polypeptide and 33% fewer neurons for arginine vasopressin in patients with HD (P = 0.002 and P = 0.027). The total amount of vasoactive intestinal polypeptide and arginine vasopressin messenger RNA was unchanged. No change was observed in the number of melatonin 1 or 2 receptor immunoreactive neurons.
CONCLUSIONS: These findings indicate posttranscriptional neuropeptide changes in the suprachiasmatic nucleus of patients with HD, and suggest that sleep and circadian rhythm disorders in these patients may at least partly arise from suprachiasmatic nucleus dysfunction.
Daniel J van Wamelen; N Ahmad Aziz; Jasper J Anink; Robin van Steenhoven; Debora Angeloni; Franco Fraschini; Ralf Jockers; Raymund A C Roos; Dick F Swaab
Related Documents :
16410668 - High risk of osteopenia and bone derangement in postsurgical patients with craniopharyn...
18405718 - Bone health in patients with cloacal exstrophy and persistent cloaca after bladder augm...
2651758 - 1,25(oh)2d3 administration in moderate renal failure: a prospective double-blind trial.
9329358 - Serum markers of bone and collagen turnover in patients with cushing's syndrome and in ...
22717138 - Is there change in intelligence quotient in chronically ill schizophrenia patients? a l...
16126968 - Plasminogen activator inhibitor-1 is associated with impaired endothelial function in w...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-01
Journal Detail:
Title:  Sleep     Volume:  36     ISSN:  1550-9109     ISO Abbreviation:  Sleep     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-04     Completed Date:  2013-03-22     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  7809084     Medline TA:  Sleep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  117-25     Citation Subset:  IM    
Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arginine Vasopressin / metabolism
Chronobiology Disorders / complications,  metabolism*
Circadian Rhythm
Cohort Studies
Huntington Disease / complications,  metabolism*
Hypothalamus / metabolism
In Situ Hybridization / methods
Neuropeptides / metabolism*
Sleep Disorders / complications,  metabolism*
Suprachiasmatic Nucleus / metabolism*
Vasoactive Intestinal Peptide / metabolism
Reg. No./Substance:
0/Neuropeptides; 113-79-1/Arginine Vasopressin; 37221-79-7/Vasoactive Intestinal Peptide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  In-flight sleep of flight crew during a 7-hour rest break: implications for research and flight safe...
Next Document:  Reduced sleep and low adenosinergic sensitivity in cacna1a R192Q mutant mice.